Could this drug slow ALS? phase 3 trial results are in
NCT ID NCT00330681
First seen Jan 11, 2026 · Last updated Jun 14, 2026 · Updated 20 times
Summary
This study tested a drug called MCI-186 in 206 people with ALS, a disease that weakens muscles over time. The goal was to see if the drug could slow the decline in physical function over 24 weeks compared to a placebo. Participants received daily intravenous doses, and researchers measured changes using a standard rating scale.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.